| Private Placement / Financing Transactions
Nuvig Therapeutics: The company raised $161 million of Series B venture funding in a deal led by Sanofi Ventures on December 5, 2024. Abrdn, Novo Holdings, Leaps by Bayer, Norwest Venture Partners, Bristol-Myers Squibb Foundation, Blue Owl Capital , and other undisclosed investors also participated in the round. The company is a developer of therapies designed to induce natural mechanisms to restore immune homeostasis and rebalance immune function.
Maze Therapeutics: The company raised $115 million in Series D venture funding in a deal led by Frazier Healthcare Partners and Deep Track Capital on December 3, 2024, putting the company’s pre-money valuation at $445 million. GV, Foresite Capital, Casdin Capital, ARCH Venture Partners, Moore Strategic Ventures, General Catalyst, Andreessen Horowitz, Third Rock Ventures, Woodline Partners, Janus Henderson Investors, Logos Capital, Piper Sandler and Matrix Capital Management also participated in the round. The company is developing medicines designed to imitate the effects of rare, naturally occurring, protective genetic variants and help halt the progression and potentially reverse the effects of kidney disease.
Cleerly: The company raised $106 million of Series C venture funding in a deal led by Insight Partners on December 4, 2024. Battery Ventures also participated in the round. The company is a developer of a healthcare platform designed to treat coronary artery disease.
KisoJi: The company raised $41 million of venture funding in a deal led by Investissement Québec and Lumira Ventures on December 2, 2024. adMare Bioinnovations, Fonds de solidarite FTQ and Remiges Ventures also participated in the round. The company is a developer of multi-specific antibodies intended to address targets in oncology and other diseases.
Natrox: The company raised $33 million of Series C venture funding in a deal led by Wealth Club, Meltwind Advisory and Amadeus Capital Partners on December 2, 2024. The company is a developer of a wound therapy device designed to improve the quality of life for patients with chronic wounds.
miDiagnostics: The company raised $30 million of Series D venture funding in a deal led by Thermo Fisher Scientific on December 4, 2024. Pamica, VMF Invest, Alychlo and other undisclosed investors also participated in the round. The company is a developer of lab-on-chip technology designed to bring miniaturized lab-quality tests with high precision liquid control and ultra-fast PCR.
Merative: The company received $25 million of development capital from Morgan Health on December 3, 2024. The company is a developer of healthcare data analytics software intended for healthcare and government social services.
Aramis Biotechnologies: The company raised CAD 30 million of Series A venture funding from undisclosed investors on December 4, 2024. The company is an operator of a biotechnology firm intended to develop advanced plant-based vaccines and therapeutics against influenza and other diseases.
Droxi: The company raised $21 million of Series A venture funding in a deal led by Drive Capital on December 3, 2024. Verissimo Ventures, AirAngels, Elad Litman, and Lurie Consulting also participated in the round. The company is a developer of a clinical workflow platform designed to streamline and automate administrative tasks.
Luminate Medical: The company raised $17.5 million of Series A venture funding in a deal led by Atlantic Bridge Capital and ARTIS Ventures on December 4, 2024. SciFounders, Faber Ventures, Metaplanet Holdings, 8VC, Calm Ventures, Finn Murphy, Steve Pacelli and Lachy Groom also participated in the round. The company is a developer of a medical device designed to prevent hair loss during chemotherapy.
Orakl Oncology: The company closed on EUR 11 million of an undisclosed targeted amount of venture funding from Singular. on December 3, 2024. The company is a developer of a tech bio platform designed to accelerate drug discovery in oncology.
DermaSensor: The company raised $8.9 million of venture funding from undisclosed investors on December 4, 2024. The company is a developer of a skin cancer evaluation technology designed to provide spectroscopy and machine learning technologies to detect skin cancer early.
Abselion: The company raised GBP 6.6 million of Series A venture funding in a deal led by M Ventures on December 4, 2024. BGF, BioProcess360, Celsius Industries, and R42 Group also participated in the round. The company is a developer of biosensors technologies designed to simplify the analysis of proteins and small molecules for pharma research and manufacturing.
NUA Surgical: The company raised EUR 6.5 million of Series A venture funding led by EQT Life Sciences on December 6, 2024. The company is an operator of a medical device business intended to create innovative surgical assistance for women’s health and improve C-sections.
Ambient Biosciences: The company raised $4.2 million of venture funding from undisclosed investors on December 2, 2024. The company is a developer of a biopreservation technology designed to eliminate cold chain reliance and improve global health equity through the use of innovative biomolecule stabilization technology.
|
